Skip to main content
. Author manuscript; available in PMC: 2016 Nov 1.
Published in final edited form as: JAMA Oncol. 2015 Nov;1(8):1128–1132. doi: 10.1001/jamaoncol.2015.1618

Table 1.

Clinicopathologic and coverage data for sequenced samples

Patient Age Primary Tumor Type (Stage) Site gDNA isolated (ng) Mapped Reads % reads on target Average coverage depth Target bases at 100X coverage Total Called variants1 Variants passing filtering2 Prioritized variants3
1 53 HGSC (IIC) Tube 89 1,599,999 93% 621x 89% 192 2 2
Ovary 86 806,616 93% 333x 82% 169 3 3
2 48 HGSC (IIIC) Tube 176 1,940,650 94% 752x 90% 232 2 2
Ovary 1,864 859,438 97% 354x 89% 192 3 2
3 53 UEC, FIGO 1 (IIIA) Tube 228 1,844,577 94% 690x 84% 210 1 1
Ovary 452 803,820 98% 331x 83% 160 6 5
4 62 UEC, FIGO 1 (IB) Tube 16 1,376,506 93% 510x 82% 514 3 3
Ovary 436 736,811 93% 293x 85% 164 3 2
Median 202 1,117,972 94% 432x 85% 192 3 2

HGSC= High grade serous carcinoma, UEC= Uterine endometrioid carcinoma, gDNA= genomic DNA.

1

Variants called by automated low stringency variant calling.

2

Variants passing filtering of technical artifacts, poorly supported variants, germline SNPs and synonymous/non-coding variants.

3

Variants passing filtering described in 2 and prioritized by Oncomine analysis as likely driving oncogenic or tumor suppressive mutations. Known deleterious germline alterations in BRCA1/2 are also included in this total. These variants are shown in Table 2.